Ilsung Pharmaceuticals Co., Ltd. (003120.KS)
KRW 15970.0
(-0.19%)
KRW 15970.0
(-0.19%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 31.24 Billion KRW | 51.35% |
| 2022 | 20.64 Billion KRW | 65.42% |
| 2021 | 12.47 Billion KRW | -4.98% |
| 2020 | 13.13 Billion KRW | -7.17% |
| 2019 | 14.14 Billion KRW | -8.05% |
| 2018 | 15.38 Billion KRW | -33.17% |
| 2017 | 23.02 Billion KRW | 14.49% |
| 2016 | 20.1 Billion KRW | 12.61% |
| 2015 | 17.85 Billion KRW | 0.95% |
| 2014 | 17.68 Billion KRW | -12.13% |
| 2013 | 20.13 Billion KRW | 12.65% |
| 2012 | 17.87 Billion KRW | -16.4% |
| 2011 | 21.37 Billion KRW | 4.52% |
| 2010 | 20.45 Billion KRW | -19.93% |
| 2009 | 25.54 Billion KRW | 42.18% |
| 2008 | 17.96 Billion KRW | 13.41% |
| 2007 | 15.84 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 31.12 Billion KRW | -0.82% |
| 2024 Q1 | 31.38 Billion KRW | 0.47% |
| 2023 Q4 | 31.24 Billion KRW | -10.84% |
| 2023 Q1 | 22.81 Billion KRW | 10.53% |
| 2023 FY | 31.24 Billion KRW | 51.35% |
| 2023 Q3 | 35.03 Billion KRW | 20.91% |
| 2023 Q2 | 28.97 Billion KRW | 27.01% |
| 2022 Q2 | 15.2 Billion KRW | 14.76% |
| 2022 Q1 | 13.24 Billion KRW | 6.16% |
| 2022 FY | 20.64 Billion KRW | 65.42% |
| 2022 Q4 | 20.64 Billion KRW | 12.84% |
| 2022 Q3 | 18.29 Billion KRW | 20.33% |
| 2021 Q2 | 13.75 Billion KRW | 1.54% |
| 2021 FY | 12.47 Billion KRW | -4.98% |
| 2021 Q4 | 12.47 Billion KRW | -1.86% |
| 2021 Q1 | 13.54 Billion KRW | 3.16% |
| 2021 Q3 | 12.71 Billion KRW | -7.57% |
| 2020 Q2 | 14.65 Billion KRW | 10.85% |
| 2020 Q1 | 13.22 Billion KRW | -6.54% |
| 2020 Q3 | 14.74 Billion KRW | 0.61% |
| 2020 FY | 13.13 Billion KRW | -7.17% |
| 2020 Q4 | 13.13 Billion KRW | -10.94% |
| 2019 Q2 | 15.41 Billion KRW | 0.73% |
| 2019 Q4 | 14.14 Billion KRW | -11.92% |
| 2019 FY | 14.14 Billion KRW | -8.05% |
| 2019 Q1 | 15.3 Billion KRW | -0.53% |
| 2019 Q3 | 16.06 Billion KRW | 4.19% |
| 2018 FY | 15.38 Billion KRW | -33.17% |
| 2018 Q2 | 17.81 Billion KRW | -7.99% |
| 2018 Q4 | 15.38 Billion KRW | -18.35% |
| 2018 Q1 | 19.35 Billion KRW | -15.91% |
| 2018 Q3 | 18.84 Billion KRW | 5.78% |
| 2017 Q3 | 22.79 Billion KRW | 12.46% |
| 2017 Q1 | 21.19 Billion KRW | 5.41% |
| 2017 FY | 23.02 Billion KRW | 14.49% |
| 2017 Q4 | 23.02 Billion KRW | 1.01% |
| 2017 Q2 | 20.26 Billion KRW | -4.39% |
| 2016 Q3 | 19.14 Billion KRW | -2.55% |
| 2016 FY | 20.1 Billion KRW | 12.61% |
| 2016 Q4 | 20.1 Billion KRW | 5.05% |
| 2016 Q2 | 19.64 Billion KRW | 21.05% |
| 2016 Q1 | 16.22 Billion KRW | -9.12% |
| 2015 Q2 | 19 Billion KRW | -5.24% |
| 2015 Q3 | 21.09 Billion KRW | 11.02% |
| 2015 Q4 | 17.85 Billion KRW | -15.37% |
| 2015 FY | 17.85 Billion KRW | 0.95% |
| 2015 Q1 | 20.05 Billion KRW | 13.37% |
| 2014 Q3 | 18.57 Billion KRW | 5.41% |
| 2014 Q2 | 17.62 Billion KRW | -0.64% |
| 2014 FY | 17.68 Billion KRW | -12.13% |
| 2014 Q4 | 17.68 Billion KRW | -4.78% |
| 2014 Q1 | 17.73 Billion KRW | -11.89% |
| 2013 Q3 | 16.33 Billion KRW | -2.51% |
| 2013 Q4 | 20.13 Billion KRW | 23.24% |
| 2013 FY | 20.13 Billion KRW | 12.65% |
| 2013 Q1 | 18.42 Billion KRW | 3.1% |
| 2013 Q2 | 16.75 Billion KRW | -9.06% |
| 2012 Q4 | 17.87 Billion KRW | 0.47% |
| 2012 Q3 | 17.78 Billion KRW | 0.62% |
| 2012 Q2 | 17.67 Billion KRW | -5.81% |
| 2012 FY | 17.87 Billion KRW | -16.4% |
| 2012 Q1 | 18.76 Billion KRW | -12.21% |
| 2011 Q3 | 17.7 Billion KRW | -10.66% |
| 2011 Q1 | 19.49 Billion KRW | -4.68% |
| 2011 Q2 | 19.81 Billion KRW | 1.67% |
| 2011 FY | 21.37 Billion KRW | 4.52% |
| 2011 Q4 | 21.37 Billion KRW | 20.73% |
| 2010 Q2 | 19.38 Billion KRW | -17.25% |
| 2010 Q1 | 23.42 Billion KRW | -8.31% |
| 2010 Q4 | 20.45 Billion KRW | 6.6% |
| 2010 Q3 | 19.18 Billion KRW | -1.0% |
| 2010 FY | 20.45 Billion KRW | -19.93% |
| 2009 Q4 | 25.54 Billion KRW | 46.26% |
| 2009 Q3 | 17.46 Billion KRW | 18.0% |
| 2009 Q2 | 14.8 Billion KRW | -8.83% |
| 2009 Q1 | 16.23 Billion KRW | -9.64% |
| 2009 FY | 25.54 Billion KRW | 42.18% |
| 2008 Q1 | 15.35 Billion KRW | -3.04% |
| 2008 Q2 | 15.95 Billion KRW | 3.89% |
| 2008 FY | 17.96 Billion KRW | 13.41% |
| 2008 Q3 | 16.49 Billion KRW | 3.39% |
| 2008 Q4 | 17.96 Billion KRW | 8.89% |
| 2007 Q2 | 16.96 Billion KRW | 19.17% |
| 2007 Q3 | 13.01 Billion KRW | -23.26% |
| 2007 FY | 15.84 Billion KRW | 0.0% |
| 2007 Q4 | 15.84 Billion KRW | 21.67% |
| 2007 Q1 | 14.23 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 29.243% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 73.492% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 65.732% |
| HANDOK Inc. | 94.46 Billion KRW | 66.929% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -47.063% |
| Yuhan Corporation | 284.75 Billion KRW | 89.029% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 73.141% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -92.148% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 89.183% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | 3.531% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 49.387% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -60.398% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -3.172% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | 35.383% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 29.243% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | 11.188% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | 35.088% |
| JW Holdings Corporation | 147.58 Billion KRW | 78.833% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 63.083% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 88.05% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 70.553% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 42.064% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -15.715% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | 3.908% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 71.539% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 29.243% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 83.439% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 87.066% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 70.553% |
| Yuhan Corporation | 284.75 Billion KRW | 89.029% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 75.063% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 49.601% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 87.977% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 70.553% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 60.754% |
| Korea United Pharm Inc. | 49.14 Billion KRW | 36.428% |
| CKD Bio Corp. | 69.08 Billion KRW | 54.777% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 70.269% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 55.81% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | 42.209% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 42.064% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 83.96% |
| Boryung Corporation | 189.8 Billion KRW | 83.541% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 45.029% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 49.387% |
| JW Lifescience Corporation | 23.39 Billion KRW | -33.516% |